Clinical Trial to Evaluate the Bioavailability and Safety of AGSAV301
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 40 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult males 20 to 40 years at screening.
body weight ≥ 45kg and within ± 20% of the ideal body weight : Ideal body weight = (height [cm] - 100) x 0.9
Be able to collect blood for study and visit for follow-up period
Subject who agrees to participate in this study and give written informed consent
Have history of significant hepatic, renal, gastrointestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric, hematologic, cardiovascular diseases
Have a gastrointestinal disease(ex : Crohn's disease, gastrointestinal ulcer)or surgery(except for Appendectomy, Hernia repair) affected the absorption of medications
Inappropriate in Screening test (interview, vital sigh, BP, 12-lead ECG, laboratory test etc.)
Hypersensitivity reactions to drugs or clinically significant hypersensitivity reactions in the history of amlodipine or valsartan
drug abuse, or have a history of drug abuse showed a positive for the screening test on urine : amphetamine, barbiturate, cocaine, opiates, benzodiazepines, cannabinoids, methadone etc.
Subject who takes herbal medicine within 30 days, ethical drug within 14 days, OTC within 7 days before the beginning of administration of investigational drug
Unusual diet affected the absorption, distribution, metabolism, excretion of medications
Subject who treated with any investigational drugs within 60 days before the administration of investigational drug
Previously donate whole blood within 60 days or component blood within 30 days or transfusion within 30 days
Subject who takes inhibitors and inducers of drug metabolizing enzyme (Barbiturates etc.) within 30days
Subject who have taken habitually caffeine (caffeine > 5 units/day)
Subject who have drunken habitually (alcohol > 21 units/week, 1 unit = pure alcohol 10ml)or who are unable to quit drinking during this study or smoker
positive for Hepatitis B, Hepatitis C, HIV or Syphilis
Blood Pressure is not in the range of "140 > sitting SBP ≥ 90mmHg, 90 > sitting DBP ≥ 60mmHg"
Pulse rate is not in the range of "95 > sitting Pulse Rate ≥ 45bpm (beats per minute)"
AST, ALT, total bilirubin over twice of reference range
Subjects deemed ineligible by investigator based on other reasons